PDB Short entry for 2VV4 HEADER RECEPTOR 02-JUN-08 2VV4 TITLE HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXOOTE COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN, RESIDUES 202-475; COMPND 5 SYNONYM: PPAR GAMMA, NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C MEMBER 3; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: 6-OXOOTE; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 10 CHAIN: B; COMPND 11 FRAGMENT: LIGAND BINDING DOMAIN, RESIDUES 202-475; COMPND 12 SYNONYM: PPAR GAMMA, NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C MEMBER 3; COMPND 13 ENGINEERED: YES; COMPND 14 OTHER_DETAILS: 6-OXOOTE SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 8 EXPRESSION_SYSTEM_VARIANT: ROSETTA; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET30A MODIFIED; SOURCE 10 MOL_ID: 2; SOURCE 11 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 12 ORGANISM_COMMON: HUMAN; SOURCE 13 ORGANISM_TAXID: 9606; SOURCE 14 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 15 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 16 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 17 EXPRESSION_SYSTEM_VARIANT: ROSETTA; SOURCE 18 EXPRESSION_SYSTEM_PLASMID: PET30A MODIFIED KEYWDS RECEPTOR, NUCLEAR RECEPTOR, LIGAND BINDING DOMAIN, OXIDISED FATTY KEYWDS 2 ACID, TRANSCRIPTION FACTOR EXPDTA X-RAY DIFFRACTION AUTHOR T.ITOH,L.FAIRALL,J.W.R.SCHWABE REVDAT 6 08-MAY-19 2VV4 1 REMARK REVDAT 5 06-MAR-19 2VV4 1 REMARK LINK REVDAT 4 06-JUN-12 2VV4 1 SOURCE JRNL REMARK VERSN REVDAT 4 2 1 FORMUL REVDAT 3 24-FEB-09 2VV4 1 VERSN REVDAT 2 28-OCT-08 2VV4 1 JRNL REMARK REVDAT 1 19-AUG-08 2VV4 0 JRNL AUTH T.ITOH,L.FAIRALL,K.AMIN,Y.INABA,A.SZANTO,B.L.BALINT,L.NAGY, JRNL AUTH 2 K.YAMAMOTO,J.W.R.SCHWABE JRNL TITL STRUCTURAL BASIS FOR THE ACTIVATION OF PPARG BY OXIDISED JRNL TITL 2 FATTY ACIDS JRNL REF NAT.STRUCT.MOL.BIOL. V. 15 924 2008 JRNL REFN ISSN 1545-9993 JRNL PMID 19172745 JRNL DOI 10.1038/NSMB.1474 REMARK 2 REMARK 2 RESOLUTION. 2.35 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.2 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : MLF REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.35 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 51.02 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1765036.140 REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.4 REMARK 3 NUMBER OF REFLECTIONS : 53512 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.226 REMARK 3 FREE R VALUE : 0.252 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 2671 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.005 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.35 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.50 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.50 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 8463 REMARK 3 BIN R VALUE (WORKING SET) : 0.2940 REMARK 3 BIN FREE R VALUE : 0.2930 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.30 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 380 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.015 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4001 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 42 REMARK 3 SOLVENT ATOMS : 144 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 27.20 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 42.80 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.20000 REMARK 3 B22 (A**2) : 12.55000 REMARK 3 B33 (A**2) : -12.75000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 2.62000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.30 REMARK 3 ESD FROM SIGMAA (A) : 0.30 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.35 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.30 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.009 REMARK 3 BOND ANGLES (DEGREES) : 1.100 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 19.10 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.820 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.200 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.080 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 1.860 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 2.920 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.35 REMARK 3 BSOL : 42.57 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : 6OC_PA.PARAM REMARK 3 PARAMETER FILE 4 : 6OB_PA.PARAM REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : 6OC_PA.TOP REMARK 3 TOPOLOGY FILE 4 : 6OB_PA.TOP REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: BULK SOLVENT MODEL USED REMARK 4 REMARK 4 2VV4 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 02-JUN-08. REMARK 100 THE DEPOSITION ID IS D_1290036465. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 16-NOV-07 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-3 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.93 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 53512 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.350 REMARK 200 RESOLUTION RANGE LOW (A) : 51.030 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 6.900 REMARK 200 R MERGE (I) : 0.12000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 15.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.35 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.48 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.8 REMARK 200 DATA REDUNDANCY IN SHELL : 7.20 REMARK 200 R MERGE FOR SHELL (I) : 0.32000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 5.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 2I4P REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.50 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.80 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM REMARK 280 TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 REMARK 280 DEGREES CELSIUS, VAPOR DIFFUSION, TEMPERATURE 295K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 46.89000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 30.79000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 46.89000 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 30.79000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 202 REMARK 465 ALA A 203 REMARK 465 LEU A 204 REMARK 465 LYS A 240 REMARK 465 THR A 241 REMARK 465 LYS A 261 REMARK 465 ILE A 262 REMARK 465 LYS A 263 REMARK 465 PHE A 264 REMARK 465 LYS A 265 REMARK 465 HIS A 266 REMARK 465 ILE A 267 REMARK 465 THR A 268 REMARK 465 PRO A 269 REMARK 465 LEU A 270 REMARK 465 GLN A 271 REMARK 465 GLU A 272 REMARK 465 GLN A 273 REMARK 465 SER A 274 REMARK 465 LYS A 275 REMARK 465 LEU A 476 REMARK 465 TYR A 477 REMARK 465 GLY B 202 REMARK 465 ALA B 203 REMARK 465 LEU B 204 REMARK 465 ASN B 205 REMARK 465 LYS B 240 REMARK 465 LYS B 261 REMARK 465 ILE B 262 REMARK 465 LYS B 263 REMARK 465 PHE B 264 REMARK 465 LYS B 265 REMARK 465 HIS B 266 REMARK 465 ILE B 267 REMARK 465 THR B 268 REMARK 465 PRO B 269 REMARK 465 LEU B 270 REMARK 465 GLN B 271 REMARK 465 GLU B 272 REMARK 465 GLN B 273 REMARK 465 SER B 274 REMARK 465 GLU B 460 REMARK 465 THR B 461 REMARK 465 ASP B 462 REMARK 465 MET B 463 REMARK 465 SER B 464 REMARK 465 LEU B 465 REMARK 465 HIS B 466 REMARK 465 ASP B 475 REMARK 465 LEU B 476 REMARK 465 TYR B 477 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR B 238 -100.43 -115.33 REMARK 500 THR B 242 69.28 -104.19 REMARK 500 HIS B 425 58.17 -141.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH B2035 DISTANCE = 6.11 ANGSTROMS REMARK 600 REMARK 600 HETEROGEN REMARK 600 REMARK 600 6-OXOOCTADECATRIENOIC ACID (6OC): LIGAND IS COVALENTLY REMARK 600 COUPLED AT C8 TO CYS285 IN MONOMER A REMARK 600 6-OXOOCTADECATRIENOIC ACID (6OB): LIGAND IS COVALENTLY REMARK 600 COUPLED AT C10 TO CYS285 IN MONOMER B REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 6OC A 1476 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 6OB B 1475 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2FVJ RELATED DB: PDB REMARK 900 A NOVEL ANTI-ADIPOGENIC PARTIAL AGONIST OF PEROXISOMEPROLIFERATOR- REMARK 900 ACTIVATED RECEPTOR-GAMMA ( PPARG) RECRUITSPPARG-COACTIVATOR-1 ALPHA REMARK 900 ( PGC1A) BUT POTENTIATES INSULINSIGNALING IN VITRO REMARK 900 RELATED ID: 1FM9 RELATED DB: PDB REMARK 900 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THEHETERODIMER OF REMARK 900 THE HUMAN RXRALPHA AND PPARGAMMA LIGANDBINDING DOMAINS RESPECTIVELY REMARK 900 BOUND WITH 9-CIS RETINOIC ACIDAND GI262570 AND CO-ACTIVATOR REMARK 900 PEPTIDES. REMARK 900 RELATED ID: 2PRG RELATED DB: PDB REMARK 900 LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR REMARK 900 ACTIVATED RECEPTOR GAMMA REMARK 900 RELATED ID: 1KNU RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATORACTIVATED REMARK 900 RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETICAGONIST REMARK 900 RELATED ID: 1RDT RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A NEW REXINOID BOUND TO THE RXRALPHALIGAND REMARK 900 BINDING DOAMIN IN THE RXRALPHA/PPARGAMMA HETERODIMER REMARK 900 RELATED ID: 1I7I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMANPPAR-GAMMA REMARK 900 IN COMPLEX WITH THE AGONIST AZ 242 REMARK 900 RELATED ID: 3PRG RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED REMARK 900 RECEPTOR REMARK 900 RELATED ID: 1K74 RELATED DB: PDB REMARK 900 THE 2.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THEHETERODIMER OF REMARK 900 THE HUMAN PPARGAMMA AND RXRALPHA LIGANDBINDING DOMAINS RESPECTIVELY REMARK 900 BOUND WITH GW409544 AND 9- CISRETINOIC ACID AND CO-ACTIVATOR REMARK 900 PEPTIDES. REMARK 900 RELATED ID: 1FM6 RELATED DB: PDB REMARK 900 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THEHETERODIMER OF REMARK 900 THE HUMAN RXRALPHA AND PPARGAMMA LIGANDBINDING DOMAINS RESPECTIVELY REMARK 900 BOUND WITH 9-CIS RETINOIC ACIDAND ROSIGLITAZONE AND CO-ACTIVATOR REMARK 900 PEPTIDES. REMARK 900 RELATED ID: 1ZGY RELATED DB: PDB REMARK 900 STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSIONOF THE REMARK 900 ORPHAN NUCLEAR RECEPTOR LRH -1 BY SHP REMARK 900 RELATED ID: 1PRG RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR REMARK 900 ACTIVATED RECEPTOR GAMMA REMARK 900 RELATED ID: 2F4B RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMANPPAR-GAMMA REMARK 900 IN COMPLEX WITH AN AGONIST REMARK 900 RELATED ID: 2VST RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 13-(S)-HODE REMARK 900 RELATED ID: 2G0H RELATED DB: PDB REMARK 900 STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPARPARTIAL REMARK 900 AGONISTS: VIRTUAL SCREENING, X-RAY CRYSTALLOGRAPHYAND IN VITRO/ IN REMARK 900 VIVO BIOLOGICAL ACTIVITIES REMARK 900 RELATED ID: 2VSR RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 9-(S)-HODE REMARK 900 RELATED ID: 1WM0 RELATED DB: PDB REMARK 900 PPARGAMMA IN COMPLEX WITH A 2-BABA COMPOUND REMARK 900 RELATED ID: 4PRG RELATED DB: PDB REMARK 900 0072 PARTIAL AGONIST PPAR GAMMA COCRYSTAL REMARK 900 RELATED ID: 2G0G RELATED DB: PDB REMARK 900 STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPARPARTIAL REMARK 900 AGONISTS: VIRTUAL SCREENING, X-RAY CRYSTALLOGRAPHYAND IN VITRO/ IN REMARK 900 VIVO BIOLOGICAL ACTIVITIES REMARK 900 RELATED ID: 1NYX RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATORACTIVATED REMARK 900 RECEPTOR GAMMA IN COMPLEX WITH AN AGONIST REMARK 900 RELATED ID: 2VV0 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH DHA REMARK 900 RELATED ID: 2VV2 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-HEPA REMARK 900 RELATED ID: 2VV3 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-OXODHA REMARK 900 RELATED ID: 2VV1 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-HDHA REMARK 999 REMARK 999 SEQUENCE REMARK 999 RESIDUE NUMBERING CORRESPONDS TO ISOFORM 1 DBREF 2VV4 A 202 203 PDB 2VV4 2VV4 202 203 DBREF 2VV4 A 204 477 UNP P37231 PPARG_HUMAN 202 475 DBREF 2VV4 B 202 203 PDB 2VV4 2VV4 202 203 DBREF 2VV4 B 204 477 UNP P37231 PPARG_HUMAN 202 475 SEQADV 2VV4 GLN B 253 UNP P37231 ASN 251 CONFLICT SEQRES 1 A 276 GLY ALA LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU SEQRES 2 A 276 ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO SEQRES 3 A 276 LEU THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS SEQRES 4 A 276 THR THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SEQRES 5 A 276 SER LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS SEQRES 6 A 276 ILE THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE SEQRES 7 A 276 ARG ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA SEQRES 8 A 276 VAL GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY SEQRES 9 A 276 PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU SEQRES 10 A 276 LYS TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SEQRES 11 A 276 SER LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY SEQRES 12 A 276 GLN GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG SEQRES 13 A 276 LYS PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE SEQRES 14 A 276 ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP SEQRES 15 A 276 LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP SEQRES 16 A 276 ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE SEQRES 17 A 276 GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS SEQRES 18 A 276 LEU ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU SEQRES 19 A 276 LEU GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU SEQRES 20 A 276 HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR SEQRES 21 A 276 ASP MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS SEQRES 22 A 276 ASP LEU TYR SEQRES 1 B 276 GLY ALA LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU SEQRES 2 B 276 ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO SEQRES 3 B 276 LEU THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS SEQRES 4 B 276 THR THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET GLN SEQRES 5 B 276 SER LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS SEQRES 6 B 276 ILE THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE SEQRES 7 B 276 ARG ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA SEQRES 8 B 276 VAL GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY SEQRES 9 B 276 PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU SEQRES 10 B 276 LYS TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SEQRES 11 B 276 SER LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY SEQRES 12 B 276 GLN GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG SEQRES 13 B 276 LYS PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE SEQRES 14 B 276 ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP SEQRES 15 B 276 LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP SEQRES 16 B 276 ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE SEQRES 17 B 276 GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS SEQRES 18 B 276 LEU ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU SEQRES 19 B 276 LEU GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU SEQRES 20 B 276 HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR SEQRES 21 B 276 ASP MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS SEQRES 22 B 276 ASP LEU TYR HET 6OC A1476 21 HET 6OB B1475 21 HETNAM 6OC (8R,9Z,12Z)-8-HYDROXY-6-OXOOCTADECA-9,12-DIENOIC ACID HETNAM 6OB (8E,10S,12Z)-10-HYDROXY-6-OXOOCTADECA-8,12-DIENOIC ACID FORMUL 3 6OC C18 H30 O4 FORMUL 4 6OB C18 H30 O4 FORMUL 5 HOH *144(H2 O) HELIX 1 1 ASN A 205 PHE A 226 1 22 HELIX 2 2 THR A 229 THR A 238 1 10 HELIX 3 3 ASP A 251 ASP A 260 1 10 HELIX 4 4 GLU A 276 ILE A 303 1 28 HELIX 5 5 GLY A 305 LEU A 309 5 5 HELIX 6 6 ASP A 310 SER A 332 1 23 HELIX 7 7 ARG A 350 SER A 355 1 6 HELIX 8 8 PRO A 359 PHE A 363 5 5 HELIX 9 9 MET A 364 ASN A 375 1 12 HELIX 10 10 ALA A 376 GLU A 378 5 3 HELIX 11 11 ASP A 380 LEU A 393 1 14 HELIX 12 12 ASN A 402 HIS A 425 1 24 HELIX 13 13 GLN A 430 GLU A 460 1 31 HELIX 14 14 HIS A 466 TYR A 473 1 8 HELIX 15 15 PRO B 206 PHE B 226 1 21 HELIX 16 16 THR B 229 THR B 238 1 10 HELIX 17 17 ASP B 251 GLU B 259 1 9 HELIX 18 18 GLU B 276 ILE B 303 1 28 HELIX 19 19 ASP B 310 SER B 332 1 23 HELIX 20 20 ARG B 350 LEU B 356 1 7 HELIX 21 21 PRO B 359 PHE B 363 5 5 HELIX 22 22 MET B 364 ALA B 376 1 13 HELIX 23 23 ASP B 380 LEU B 393 1 14 HELIX 24 24 ASN B 402 HIS B 425 1 24 HELIX 25 25 GLN B 430 THR B 459 1 30 HELIX 26 26 PRO B 467 TYR B 473 1 7 SHEET 1 AA 4 PHE A 247 ILE A 249 0 SHEET 2 AA 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 AA 4 GLY A 338 ILE A 341 -1 O VAL A 339 N MET A 348 SHEET 4 AA 4 MET A 334 ASN A 335 -1 O ASN A 335 N GLY A 338 SHEET 1 BA 4 PHE B 247 ILE B 249 0 SHEET 2 BA 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 BA 4 GLY B 338 ILE B 341 -1 O VAL B 339 N MET B 348 SHEET 4 BA 4 MET B 334 ASN B 335 -1 O ASN B 335 N GLY B 338 LINK SG CYS A 285 C8 6OC A1476 1555 1555 1.82 LINK SG CYS B 285 C10 6OB B1475 1555 1555 1.78 CISPEP 1 LYS A 358 PRO A 359 0 -0.21 CISPEP 2 LYS B 358 PRO B 359 0 -0.06 SITE 1 AC1 11 CYS A 285 ARG A 288 SER A 289 HIS A 323 SITE 2 AC1 11 TYR A 327 LEU A 340 ILE A 341 SER A 342 SITE 3 AC1 11 MET A 364 HIS A 449 TYR A 473 SITE 1 AC2 7 ILE B 281 CYS B 285 ARG B 288 SER B 289 SITE 2 AC2 7 ILE B 326 LEU B 333 ILE B 341 CRYST1 93.780 61.580 118.770 90.00 103.64 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010663 0.000000 0.002588 0.00000 SCALE2 0.000000 0.016239 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008664 0.00000